BUSINESS WIRE; Thursday, February 26, 1998
The Uni-Gold(tm) HIV rapid test will be utilized in a government HIV screening program throughout Malaysia. Following local trials and evaluations, the Uni-Gold(tm) HIV product was chosen above competitive products for this program.
The simplicity of this test, which uses whole blood as a sample, was a critical factor in meeting the government's requirements and needs.
Ronan O'Caoimh, CEO of Trinity Biotech, commented, "The Uni-Gold(tm) HIV test is ideally suited to rapid, near patient testing
-- without the use of instrumentation or complex laboratory procedures
-- as it utilizes whole blood in a simple one-step procedure to give results in less than 10 minutes. We are pleased to see continuing expansion of our global distribution of this successful product."
Trinity Biotech develops, manufactures and markets diagnostic products that address all three segments of the diagnostic market: (1) rapid tests for the emerging point-of-care (POC) market, (2) simplified tests for the self-test (OTC) market, and (3) microtitre plate kits for the clinical laboratory market. The company's products are sold in over 65 countries around the world.
0-
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings.
30--jc/ny*
CONTACT: TRINITY BIOTECH PLC Jonathan O'Connell Chief Financial Officer (800) 603-8076 OR INVESTOR RELATIONS CONTACT: Lippert/Heilshorn Associates, Inc. Olga M. Fleming olga@lhai.com Ruth Markowitz ruth@lhai.com (212) 838-3777
Copyright (c) 1998/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
980226
BW980211
Copyright © 1998 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .